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ABSTRACT
A xenobank of patient-derived (PDX) ovarian tumor samples has been established 
consisting of tumors with different sensitivity to cisplatin (DDP), from very responsive 
to resistant. As the DNA repair pathway is an important driver in tumor response 
to DDP, we analyzed the mRNA expression of 20 genes involved in the nucleotide 
excision repair, fanconi anemia, homologous recombination, base excision repair, 
mismatch repair and translesion repair pathways and the methylation patterns of 
some of these genes. We also investigated the correlation with the response to 
platinum-based therapy. The mRNA levels of the selected genes were evaluated by 
Real Time-PCR (RT-PCR) with ad hoc validated primers and gene promoter methylation 
by pyrosequencing. All the DNA repair genes were variably expressed in all 42 PDX 
samples analyzed, with no particular histotype-specific pattern of expression. In 
high-grade serous/endometrioid PDXs, the CDK12 mRNA expression levels positively 
correlated with the expression of TP53BP1, PALB2, XPF and POLB. High-grade serous/
endometrioid PDXs with TP53 mutations had significantly higher levels of POLQ, 
FANCD2, RAD51 and POLB than high-grade TP53 wild type PDXs. The mRNA levels of 
CDK12, PALB2 and XPF inversely associated with the in vivo DDP antitumor activity; 
higher CDK12 mRNA levels were associated with a higher recurrence rate in ovarian 
patients with low residual tumor. These data support the important role of CDK12 in 
the response to a platinum based therapy in ovarian patients.
INTRODUCTION
Ovarian carcinoma accounts for 2% of all female 
cancers and is the fifth cause of cancer-related deaths 
[1]. Epithelial ovarian cancer (EOC) is the most common 
type (90%) and a recent classification, based on histology, 
molecular features and natural history, further divides 
EOCs into two categories [2–4]. Type I EOCs include 
low-grade serous, low-grade endometrioid, mucinous 
and clear-cell carcinomas; they are genetically stable, 
relatively indolent and generally cured by surgery alone 
and display low chemosensitivity. Type II tumors, the 
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vast majority of EOCs, are high-grade (serous and 
endometrioid) carcinomas with an aggressive clinical 
course, genetically unstable and frequently mutated in 
TP53; despite their initial good chemo-sensitivity, their 
outcome is very poor, with 30% survival after five years. 
This dismal prognosis is often due to late diagnosis, as 
symptoms do not generally appear until the disease has 
already spread outside the ovaries (FIGO stages III/IV), 
and even if most patients respond to platinum (DDP)-
based adjuvant chemotherapy, the majority eventually 
relapse with a resistant disease [5].
Inactivation of DNA repair is an important 
oncogenic event in most human cancers [6]. Mutations 
and/or loss of genes involved in different DNA repair 
pathways are associated with an increased risk of cancer. 
However, as most anticancer agents act by damaging 
DNA, lack/inactivation of these repair pathways 
renders tumors particularly susceptible to specific 
chemotherapeutic agents. The striking sensitivity of 
EOC to platinum-based therapy is thought to be related 
to underlying defects in homologous recombination (HR) 
DNA repair, called the BRCAness phenotype [7, 8]. Many 
genetic studies, and more recently The Cancer Genome 
Atlas (TCGA) project, have shown that high-grade serous 
ovarian carcinomas are characterized by genetic (germline 
and somatic mutations) and epigenetic alterations of the 
HR pathway [9]. 
Though defective HR is an important mediator of 
platinum sensitivity in EOC, repair of platinum-induced 
DNA damage does not involve only the HR pathway [10]. 
Nucleotide excision repair (NER), fanconi anemia (FA) 
and mismatch repair (MMR) are all involved in processing 
platinum-DNA lesions. More than 90% of these lesions 
are intrastrand cross-links, which are repaired by the 
NER pathway [11, 12]. Mutations leading to functional 
inactivation of NER genes lead to extreme platinum 
sensitivity, as reported in CHO NER mutant cells [13] and 
in patients with Xeroderma pigmentosum or Cockayne 
syndrome [14, 15]. Recently, 8% of high-grade serous 
EOCs from The Cancer Genome Atlas dataset were shown 
to have NER alterations, including non-synonymous or 
splice-site mutations and homozygous deletions of NER 
genes [16]. Hyper-methylation of FANCF, leading to 
lower protein levels, has been associated with sensitivity 
to DDP in ovarian cancer cells [17].
While the importance of DNA repair in the extreme 
sensitivity to DDP has been plainly demonstrated [13], 
DDP resistance has been less clearly associated with 
an increase in DNA repair capacity. There are still no 
validated biomarkers and/or functional assays correlated 
with tumor DNA repair capacity.
We recently characterized a xenobank of patient-
derived ovarian tumor samples (PDXs) and found that 
these models recapitulate the biological, histological, 
molecular and pharmacological features of the original 
human EOC [18]. This EOC-xenobank consists of tumors 
with different sensitivity to DDP from very responsive, 
to responsive and resistant tumors, reproducing well the 
clinical response to therapy in ovarian patients. As DNA 
repair is an important factor in tumor response to DDP, 
we analysed the mRNA expression of 20 genes involved 
in the NER, FA, HR, base excision repair (BER), MMR 
and translesion repair (TR) pathways and the methylation 
patterns of some of these genes; subsequently, we 
investigated the correlations between these data and 
the response to a platinum-based therapy in our PDX 
xenobank.
RESULTS
This study was done on 42 ovarian carcinoma 
PDXs, whose main characteristics are summarized in 
Table 1 and Supplementary Table 1.
mRNA expression of 20 genes involved in 
different DNA repair pathways
Supplementary Figure 1 shows a heatmap of the 
expression of the genes analysed in the panel of samples. 
There was considerable variability in expression levels 
of the individual genes (Supplementary Table 2) and no 
histotype-specific cluster was found. 
Considering that most of the DNA repair pathways 
explored are multistep processes, we looked for correlations 
between single gene expression. Supplementary Figure 2A 
shows the heat-map of correlation and Supplementary 
Figure 2B reports the correlation indexes with the 
statistically significant ones red high lightened. As our 
PDX xenobank was composed of 80% high-grade serous/
endometrioid tumors, the most clinically relevant ones, 
we decided to focus on this more homogeneous subset 
of tumors and obtained similar results (Figure 1 and 
Supplementary Table 3). Specifically, the expression of 
PALB2, FANCC, FANCD2, OGG1, POLQ, and RAD51 
genes correlated each with the expression of at least six 
other genes and in some cases genes belonging to the same 
pathway were inter-correlated (i.e. FA genes). 
CDK12 mRNA levels positively correlated with 
the expression of TP53BP1, PALB2, XPF and POLB 
genes. We analysed gene expression data from the TCGA 
database (both from microarrays and RNAseq) and, 
as detailed in Supplementary Table 4, CDK12 mRNA 
correlates with three out of four of the transcripts we found 
in our xenobank (i.e. TP53BP1, PALB2, XPF) in both 
datasets. These data are consistent with the transcriptional 
role of CDK12 in regulating the expression of some DNA 
repair genes.
No significant differences in gene expression level 
according to TP53 mutational status were found when 
all the tumor types were considered. When we focused 
on high-grade PDXs, TP53 mutated xenografts had 
significantly higher levels of POLQ, FANCD2, RAD51, 
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and POLB genes (Figure 2), even these data should be 
considered with caution considering the sample size (4 wt 
tumors vs 25 with mutated TP53).
Promoter methylation of BRCA1, ERCC1, XPA, 
MLH1, FANCF and XPG genes
We then investigated the methylation status 
of some of the DNA repair genes whose levels were 
studied. Supplementary Table 5 depicts the percentage 
of methylation in the selected promoter area of the genes 
analyzed (see Supplementary Figure 3 and Supplementary 
Table 6) and Figure 3 reports the median percentage 
methylation for BRCA1, ERCC1, XPA, MLH1 selected 
regions. BRCA1 was the most hyper-methylated gene 
with 51% of the xenografts (20 out of 39) showing all 
three promoter regions with more than 10% of CpG island 
methylated. ERCC1 was scarcely methylated, with only 
three samples (MNHOC8, MNHOC124 and MNHOC218) 
showing one promoter region with > 10% methylation. 
Xenograft MNHOC109 was the only tumor which had 
both MLH1 promoter regions hyper-methylated, while 
MNHOC500 presented 11% methylation in only one 
region; XPA promoter was methylated in only one of 
the selected regions in five out of the 39 xenografts. No 
methylation of the XPG promoter region was detected 
in any of our PDXs (Supplementary Figure 4), while the 
FANCF promoter regions in MNHOC119 and MNHOC18 
PDXs were partially methylated (Supplementary Figure 5). 
We found no correlation between the BRCA1 methylation 
status and its mRNA expression levels (data not shown).
Gene expression associated to xenografts 
response to a platinum based therapy
The relation between the antitumor activity of 
DDP and mRNA expression levels was investigated with 
a view to finding possible biomarkers of chemotherapy 
response. We again focused on high-grade serous and 
endometrioid xenografts for which an in vivo response 
to DDP was available, and which were classified as 
very responsive, responsive and resistant (summarized 
in Table 1 and Supplementary Table 1). The expression 
levels of three genes (CDK12 [p = 0.017], panel A; 
PALB2 [p = 0.019], panel B, and XPF [p = 0.016], panel 
C) were negatively associated with response to DDP, 
with higher mRNA levels in resistant xenografts than in 
responsive ones (Figure 4). 
We then looked for independent confirmation in a 
public database, using the TCGA, where the expression 
levels of these genes and clinical data, including overall 
survival, are available. As reported in Figure 4D, patients 
with higher CDK12 mRNA levels had a higher risk of 
recurrence (HR:1.119, 95% CI 0.9188–1.564; p = 0.179), 
though the difference did not reach statistical significance; 
no association was found for PALB2 and XPF expression 
levels. The analysis suffered from the fact that patients 
with CDK12 mutations were also included. As these 
mutations have been reported to disable the kinase 
catalytic activity [19], we considered these patients as 
having zero protein levels. When the analysis was done 
on patients stratified for residual tumor (RT) after surgery 
(more or less than 2 cm) a high level of CDK12 predicted 
Figure 1: Heatmap of the correlation between single genes’ expression in the subset of high-grade PDXs.
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a worse prognosis for patients with a RT smaller than 
2 cm than those with lower CDK12 levels but also RT 
< 1 cm (HH:1.295, 95% CI 1.016–1.651; p = 0.0367) 
(Figure 4D).
DISCUSSION
EOC is one of the most chemo-sensitive human 
tumors, being highly responsive to DDP based front-line 
therapy; however, relapses with DDP resistant disease 
occur in most cases. Understanding the molecular basis 
of the DDP tumor response would be extremely helpful 
in selecting patients who will benefit most from DDP-
based chemotherapy and redirect the less responsive 
ones to other therapies. Since DNA repair is an important 
determinant of the cellular response to DDP [20], we 
studied the expression of 20 genes, and in selected cases 
their methylation patterns, involved in the repair pathways 
of platinum-induced DNA damage in a xenobank of EOC-
PDXs recently established in our laboratory and in which 
the response to in vivo DDP treatment was available (this 
manuscript and [18]).
The study showed that: i) all the DNA repair genes 
were variably expressed in the 42 PDXs analyzed, with no 
histotype-specific cluster of expression; ii) in high-grade 
serous/endometrioid PDXs, the CDK12 mRNA levels 
positively correlated with the expression of TP53BP1, 
PALB2, XPF genes; iii) high-grade serous/endometrioid 
PDXs with TP53 mutation had significantly higher levels 
of POLQ, FANCD2, RAD51 and POLB genes than TP53 
wt PDXs; iv) except for the BRCA1 promoter, which was 
hyper-methylated in 51% of the xenografts, all the other 
DNA repair gene promoters investigated were scarcely 
methylated; v) the mRNA levels of CDK12, PALB2 and 
XPF inversely correlated with the in vivo DDP antitumor 
activity; vi) higher CDK12 mRNA levels predicted worse 
prognosis in patients with residual tumor smaller than 2 cm.
All the DNA repair genes analysed were expressed, 
but no histotype-specific cluster of expression were found. 
This might be explained by the samples in our xenobank, 
where there were only two cases of mucinous and clear 
cell carcinomas and more than 80% were high-grade 
serous/endometrioid carcinomas (reflecting the percentage 
found in clinic). For this reason, we restricted our analysis 
to this specific sub-group. Interestingly, the expression of 
genes belonging to the same pathway (i.e. FA and genes 
involved in the repair of double-strand breaks) were 
interrelated with positively correlating expression levels, 
suggesting a common transcriptional control. It was 
recently reported that DNA repair genes have cell cycle-
regulated expression more frequently than average genes, 
particularly in S phase [21]. While we did not specifically 
Figure 2: Correlation between TP53 mutational status and DNA repair gene expression. In high-grade ovarian PDXs 
(n = 34) POLQ, FANCD2, RAD51 and POLB mRNA levels were significantly higher in TP53 mutated PDXs. Data are expressed as 
median ± standard deviation. p < 0.05 was considered significant.
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investigate the mitotic index in our PDXs, we collected 
tumor samples with average tumor masses of 800–1200 
mg, when they were in their exponential growing phase.
OGG1 mRNA levels were significantly correlated 
with genes involved in the removal of intra-strand 
cross-links and double-strand repair. OGG1 is a DNA 
glycosylase that removes oxidatively damaged guanines 
caused by reactive oxygen species–lesions considered 
poorly cytotoxic, but quite mutagenic [22]. While OGG1 
mRNA expression has already been reported to correlate 
with PARP1 mRNA levels, involved in the same pathway 
(i.e. BER) [23], no correlation with other DNA repair 
genes has been reported. These data may underlie a higher 
than expected cross-talk among the different DNA repair 
pathways, with OGG1 as a possible master regulator.
TP53 mutation is a key event in ovarian 
tumorigenesis and this mutation is the most frequent one 
both in early and late stage high-grade serous carcinoma 
[9, 24]. We found that TP53 mutated PDXs had higher 
POLQ, FANCD2, RAD51 and POLB mRNA levels. It 
has been recently reported that TP53 down-regulates 
several genes of the FA pathway in many tissues and 
that loss of TP53 function leads to increased expression 
of FA genes in advanced human cancers, as suggested 
by the analysis of transcriptomic data in advanced TP53 
mutated human neoplasms (i.e. ovarian adeno-carcinoma, 
liver and adeno-cortical tumors) [25]. This effect was due 
to a TP53-mediated transcriptional repression through 
E2F4 binding at FANCD2 promoter; it remains to be 
defined whether the same mechanisms apply for POLQ, 
RAD51 and POLB genes. While in murine cell lines the 
TP53 dependent down-regulation of FANCD2 was also 
associated with a decrease in repair activity, it is not yet 
clear whether higher FANCD2 levels are associated with 
more DNA repair. This is important as it would imply that 
higher FANCD2 levels are associated with a higher level 
of DNA repair and decreased sensitivity to DDP.
DNA repair genes have been found to be variably 
methylated in human cancers [26, 27]. We found that 
half of our PDXs showed hyper-methylation in GpC 
islands of BRCA1 in the three areas studied (Figure 3 
and Supplementary Figure 3); however, this was not 
correlated with BRCA1 mRNA levels. One explanation 
might be that these probes, located in the BRCA1 gene 
promoter upstream to the transcription site, differ from 
the ones whose methylation was inversely correlated 
with BRCA1 expression in the TCGA [9, 28] and triple-
negative breast cancer patients [29]. All the other genes 
analysed were scarcely methylated, confirming similar 
findings in ovarian cancer [9, 30]. MNHOC109 PDX with 
the hyper-methylated MLH1 promoter was the sample 
with the lowest MLH1 mRNA (100 times lower than 
Table 1: Characteristics of the ovarian tumors from which EOC-xenografts derived
Patient’s original diagnosis EOC-PDXs Patient’s original diagnosis EOC-PDXs
Xenograft ID Histotype Grade Stage Source TP53 DDP response
Xenograft 
ID Histotype Grade Stage Source TP53 DDP response
MNHOC239 serous G2 IV R mut  MNHOC506 serous G3 IIIC n/a* mut  
MNHOC241 serous G2 IC P wt n/a MNHOC508 serous G3 IIIC P mut  
MNHOC244 serous G2 IV P mut n/a MNHOC124 serous/endometrioid G2 IIIC P mut  
MNHOC250 serous G3 IIIC P mut n/a MNHOC212 serous/endometrioid G2 IIIC P mut  
MNHOC258 serous G3 IIIC P mut  MNHOC154 endometrioid G2 IIC R mut  
MNHOC266 serous G2 n/a n/a* mut  MNHOC218 endometrioid G3 IIIC P mut  
MNHOC76 serous G3 IIIC R* mut  MNHOC230 endometrioid G3 IIB R mut  
MNHOC18 serous G3 IV P mut  MNHOC261 endometrioid G2 IIIC P mut  
MNHOC8 serous G3 IV P* mut  MNHOC78 endometrioid G2 IIIC R mut  
MNHOC107 serous G3 IIIC R mut  MNHOC109 endometrioid G2 IC R wt  
MNHOC111/2 serous G3 IIIC R* mut  MNHOC503 endometrioid G3 IIIA P wt  
MNHOC22 serous G3 III R* mut  MNHOC145 endometrioid G1 IC P n.a n.a
MNHOC10 serous G3 IIIC P* mut  MNHOC79 endometrioid/clear cell G3 IIIC R* mut  
MNHOC8Y serous G3 IV R* mut  MNHOC164 mucinous G2 IV P wt  
MNHOC84 serous G3 IIIC R mut  MNHOC182 mucinous G1 IC P wt  
MNHOC106C serous G3 IIIC R mut  MNHOC119 clear cell G3 IC P wt  
MNHOC94/2C serous G2 IA R wt  MNHOC142 clear cell G3 IIIC P* mut  
MNHOC125 serous G3 IV P mut  MNHOC135 mixed mullerian G3 IIIB P mut  
MNHOC143 serous G3 IIIC P mut  MNHOC151 carcinosarcoma G3 IIB P n.a n.a
MNHOC149 serous G3 IIIC P mut n.a MNHOC9 not classified na IIIC P mut  
MNHOC500 serous G3 IIIC P mut  MNHOC88 undifferentiated G3 IIIC R mut  
Abbreviations: EOC: epithelial ovarian carcinoma; PDXs: patient derived xenografts; P: primary tumor; R: relapse; mut: mutated; wt: wild type; n.a: not available. *Tumor cell suspension transplanted 
intraperitoneal (ip).
*DDP response: in vivo activity of DDP as described in Material and Methods. Drug activity was defined as follows: subcutaneous tumors were considered resistant with T/C ≥ 50% (black), responsive with 10 
to 50% T/C (dark grey) and very responsive with T/C ≤ 10% (light grey); intraperitoneal tumors were considered resistant with Increase in Life Span (ILS) ≤ 40%, responsive with 40 to 100% ILS, and very 
responsive with ILS ≥ 100%, according to published criteria.
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the median, data not shown). Expression of MLH1 has 
been reported to be inversely correlated with its promoter 
methylation [31] and resistance to DDP [32]; however, 
MNHOC109 showed an intermediate sensitivity to DDP 
(Table 1), suggesting that other factors contribute to 
DDP’s antitumor activity. Similar consideration should for 
MNHOC18, in which FANCF promoter methylation was 
associated with low level of mRNA (data not shown) and 
intermediate responsiveness to DDP.
Our expression data support a potential role of 
CDK12 in controlling the expression of genes involved 
in DNA repair (Figure 1). CDK12 is a kinase involved 
in positively regulating the transcription of genes 
involved in the DNA damage response, chromosome 
organization, stress induced gene activation and possibly 
RNA processing factors [33–35]. The gene has also been 
found mutated in ovarian cancer and there is evidence 
that these mutations lead to loss of function, promoting 
carcinogenesis by impairing homologous recombination 
repair (HR) and rendering cells particularly susceptible to 
different anticancer agents, such as PARP inhibitors [19, 
36, 37]. In our xenobank, CDK12 levels correlated with 
the levels of TP53BP1, PALB2, XPF and POLB mRNAs, 
involved in pathways of repair of double-strand DNA 
breaks, NER and BER; these genes are also involved in 
removal of the DDP-DNA damage. Interestingly, CDK12 
mRNA levels, with PALB2 and XPF mRNA levels 
were significantly higher in high-grade PDX models 
resistant to DDP treatment. When we looked for similar 
associations between the CDK12, PALB2 and XPF mRNA 
levels and overall survival (OS) using data from patients 
treated with platinum therapy in the recent TGCA study 
in which the corresponding tumor mRNA levels were 
quantified [9], high PALB2 and XPF mRNA levels were 
not associated with a worse OS in these patients. We 
found that high levels of CDK12 were associated with 
worse OS in patients with a residual tumor after surgery 
< 2 cm. The data, if confirmed in other cohorts of ovarian 
patients, will allow the identification of a subgroup of 
patients (high level of CDK12 mRNA and residual tumor 
< 2 cm) to be potentially enrolled in clinical trials with 
alternative therapies. These data partially agree with those 
recently published in which low CDK12 mRNA levels 
were associated with improved OS in high-grade ovarian 
carcinoma [38].
Overall, the present data suggest that the mRNA 
expression levels of some genes can be important for 
the response to DDP and they need to be prospectively 
validated in cohorts of ovarian cancer patients. We are 
aware that mRNA profiling only captures a subset of 
cancer genetic changes as other regulation mechanisms 
are important for gene expression such as microRNAs 
[39], protein phosphorylation [40] and ubiquitination [41]. 
One of the hallmark of ovarian cancer is the BRCAness 
phenotype that has been shown to predict sensitivity to 
both DDP and PARP inhibitors. This phenotype relies 
Figure 3: Median % methylation in the CpG islands of BRCA1, ERCC1, XPA, MLH1. Each bar represents the different CpG 
islands analyzed.
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on germline/somatic mutations in BRCA1/2 genes and/
or other genes involved in HR (i.e. BROCA-test: exome 
sequencing to detect mutations in genes encoding proteins 
involved in HR pathway) [42]; on HDR score that uses 
a combination of telomeric allelic imbalance, loss of 
heterozygosity and long segment transition, which 
all separately associated with BRCA1/2 mutation in a 
collective biomarker (i.e. Myriad myChoice-HRD) [43]; 
on mutational signatures (genomic scars) caused by loss 
of HR (i.e. BRCA mutations) [44]. Sensitivity to DDP and 
resistance to PARP inhibitors have been reported to be 
caused by mutations in genes involved in NER [16], while 
resistance to both has been seen in BRCA mutated patients 
undergoing reverse mutations on BRCA gene restoring the 
HR activity [45]. We are investigating by whole genome 
sequencing the mutational signature (s), the presence of 
telomeric imbalance and loss of heterozygosity in our 
PDX xenobank to correlate with the response to DDP and 
these findings will be reported elsewhere.
The validation of functional assays to measure DNA 
repair activity directly in tumor cells will probably have 
a more accurate predictive value than the DNA protein 
expression level. However, this is not easy to accomplish, 
even if some surrogates [20, 46] and direct tumor 
measurements of DNA repair capacity have been proposed 
[47]. We believe our PDXs will be useful for setting up 
functional DNA repair assays, as suggested by preliminary 
data on primary cultures and/or organotypic slices to be 
correlated with the DDP pharmacological activity.
MATERIALS AND METHODS
Animals 
Female NCr-nu/nu mice obtained from Envigo 
Laboratories (Italy) were used when six to eight weeks 
old. Mice were maintained under specific pathogen-
free conditions, housed in isolated vented cages, and 
handled using aseptic procedures. The IRCCS-Istituto 
di Ricerche Farmacologiche Mario Negri adheres to the 
principles set out in the following laws, regulations and 
policies governing the care and use of laboratory animals: 
Italian Governing Law (D. lg 26/2014; Authorization 
no.19/2008-A issued March 6, 2008 by Ministry of 
Figure 4: Gene expression levels and DDP response. Panels (A–C): box plots of XPF, PALB2 and CDK12 gene expression levels 
respectively and response to DDP treatment in high-grade ovarian cancer PDXs. The circle in the PALB2 plot indicates an outlier. *p < 0.05. 
Panel (D): forest plot of the relation between gene expression and ovarian cancer patient survival. Estimated risk of recurrence in patients 
with different mRNA levels of CDK12, XPF and PALB2 genes (l- lower CI; -l upper CI; ● estimate). CDK12*: the CDK12 mRNA level 
was taken as zero in patients with CDK12 mutated; RT (residual tumor) > 2 cm; RT < 2 cm. 
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Health); Mario Negri Institutional Regulations and 
Policies providing internal authorization for persons 
conducting animal experiments (Quality Management 
System Certificate- UNI EN ISO 9001:2008– Reg, 
N°6121); the NIH Guide for the Care and Use of 
Laboratory Animals (2011 edition) and EU directive and 
guidelines (EEC Council Directive 2010/63/UE). The 
Statement of Compliance (Assurance) with the Public 
Health Service (PHS) Policy on Human Care and Use of 
Laboratory Animals was recently reviewed (9/9/2014) 
and will expire on September 30, 2019 (Animal Welfare 
Assurance #A5023-01).
Xenografts
We used a xenobank with 42 recently established 
ovarian cancer PDXs (30 of them already described 
in [18]). The study protocol for tissue collection and 
clinical information was approved by the institutional 
review board and patients provided written informed 
consent authorizing the collection and use of the tissue 
for study purposes. Their histology, TP53 status and 
response to in vivo DDP treatment are specified in 
Table 1 and Supplementary Table 1. The majority are 
high-grade serous/endometrioid PDXs with a mutated 
TP53; the whole spectrum of responses to DDP (very 
sensitive, sensitive and resistant) is presented ([18] and 
Supplementary Table 1). DDP antitumor activity was 
evaluated as previously reported. Specifically, DDP 
was given i.v. 5 mg/kg 7qx3. Drug activity was defined 
as follows: subcutaneous (sc) tumors were considered 
resistant with T/C (mean tumor weight treated/mean tumor 
weight vehicle treated mice x100) ≥ 50%, responsive 
with T/C comprises between 10% and 50% and very 
responsive with T/C ≤ 10%; intraperitoneal (ip) tumors 
were considered resistant with increase in life span (ILS-
median survival time of treated animal/median survival 
time of vehicle treated mice × 100) ≤ 40%, responsive 
with ILS from 40% to 100%, and very responsive with 
ILS ≥ 100%, according to published criteria [48, 49]. High 
grade serous and endometriod were defined as tumors with 
histological grade > 2.
RNA isolation and real time-PCR
Tumor samples were obtained from nude mice 
transplanted sc or ip with ovarian carcinomas; when 
tumor masses ranged from 800–1200 mg or the 
abdomen showed signs of ascites, tumor fragments or 
peritoneal tumor cells recovered by peritoneal lavage 
were immediately snap-frozen and kept at –80°C until 
further analysis. Tumor fragments or ascites pellets were 
homogenized with an Ultra-turrax in RNA lysis buffer 
in ice and RNA was purified using the SV Total RNA 
Purification Kit (Promega). Tumor PDX samples were 
analyzed by real time-PCR to assess the % of murine 
DNA contamination using primers specifically designed 
to distinguish human from murine actin. Only samples 
with more than 70% of human DNA were evaluated. 
Retro-transcription to cDNA was done using the High 
Capacity cDNA Archive Kit (Applied Biosystem). 
The genes selected have a key role in BER (OGG1, 
POLB and PARP1), NER (ERCC1, XPA, XPF, XPD 
and XPG), and the double strand-break repair pathways 
(TP53BP, RAD51, PALB2, BRCA1, FANCA, FANCC, 
FANCD2 and FANCF); in TLR (POLH), MMR (MLH1), 
MMEJ (POLQ) and in the transcription of some genes 
involved in the DNA repair activity (CDK12). Optimal 
primer pairs (See Supplementary Table 7) were chosen, 
spanning splice junctions, using PRIMER-3 software 
(http://primer3.ut.ee/) and the specificity was verified by 
detecting single-band amplicons of the PCR products. All 
the primers were tested for their human specificity using 
murine cDNA and different proportion of human and 
murine cDNA (data not shown) and all samples had more 
than 85% of human RNA. Absolute copy numbers of 
mRNA were determined by RT-PCR (ABI-7900, Applied 
Biosystems) with the SYBR Green technique, using an 
EPMotion 5075 robot (Eppendorf). Standard curves for 
each gene were included for absolute quantification of 
mRNA, and normalized as described below.
Methylation assay
Genomic DNA was extracted from snap-frozen 
tissues using Maxwel l16 Cell DNA Purification kit 
(Promega). One microgram of genomic DNA was 
modified with sodium bisulfite using the Epitect Bisulfite 
kit (Qiagen) according to the manufacturer’s specifications 
and as specified in Supplementary Material. 
Data and statistical analysis
PCR data were normalized using the geometric 
mean of cyclophillin (CYPA) and actin (ACTB) 
endogenous controls. The linear correlation between the 
expression levels of different repair genes was measured 
by a Pearson test. Welch t test was applied to compare 
two experimental groups (wild type-wt- vs mutated 
TP53). For comparisons of the three groups with different 
DDP responses, we applied one-way ANOVA, followed 
by a Tukey post-hoc test. High grade PDX sample was 
25 for TP53 mutated and 4 for wt; resistant, sensitive 
and very sensitive PDXs were respectively 4, 13 and 
10. Microarray gene expression data of TCGA ovarian 
serous cystadenocarcinoma samples and CDK12 co-
expression analysis were retrieved from the cBioPortal 
platform (http://www.cbioportal.org). RNA sequencing 
v.2 expression data for a subset of the same database were 
retrieved from the TCGA data portal (https://tcga-data.
nci.nih.gov).
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